title: Mumps postexposure prophylaxis with a third dose of measles-mumps-rubella vaccine, Orange County, New York, USA.
abstract: Although the measles-mumps-rubella (MMR) vaccine is not recommended for mumps postexposure prophylaxis (PEP), data on its effectiveness are limited. During the 2009-2010 mumps outbreak in the northeastern United States, we assessed effectiveness of PEP with a third dose of MMR vaccine among contacts in Orthodox Jewish households who were given a third dose within 5 days of mumps onset in the household's index patient. We compared mumps attack rates between persons who received a third MMR dose during the first incubation period after onset in the index patient and 2-dose vaccinated persons who had not. Twenty-eight (11.7%) of 239 eligible household members received a third MMR dose as PEP. Mumps attack rates were 0% among third-dose recipients versus 5.2% among 2-dose recipients without PEP (p=0.57). Although a third MMR dose administered as PEP did not have a significant effect, it may offer some benefits in specific outbreak contexts.
authors: Centers for Disease Control and Prevention, Atlanta, GA 30333, USA. AFiebelkorn@cdc.gov
authors: Amy Parker
authors: AP
authors: Fiebelkorn
authors: Jacqueline
authors: J
authors: Lawler
authors: Aaron T
authors: AT
authors: Curns
authors: Christina
authors: C
authors: Brandeburg
authors: Gregory S
authors: GS
authors: Wallace
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D008297:Male; D022542:Measles-Mumps-Rubella Vaccine / Q000276:immunology*; D009107:Mumps / Q000453:epidemiology / Q000517:prevention & control*; D009109:Mumps virus / Q000737:chemistry / Q000276:immunology*; D009518:New York; D056990:Post-Exposure Prophylaxis; D055815:Young Adult
chemical_list: D022542:Measles-Mumps-Rubella Vaccine
keywords: measles-mumps-rubella vaccine; mumps; postexposure prophylaxis; third-dose MMR vaccine intervention; viruses
references: Euro Surveill. 2010 Apr 29;15(17):
references: 20460086
references: N Engl J Med. 2012 Nov;367(18):1704-13
references: 23113481
references: Emerg Infect Dis. 2007 Jan;13(1):12-7
references: 17370510
references: Infect Dis Clin North Am. 1996 Dec;10(4):899-915
references: 8958174
references: J Infect Dis. 1988 Dec;158(6):1253-60
references: 3198938
references: Am J Epidemiol. 1989 Oct;130(4):736-49
references: 2505612
references: Pediatr Infect Dis J. 2013 Apr;32(4):374-80
references: 23099425
references: Euro Surveill. 2009 Feb 05;14(5):
references: 19215718
references: CMAJ. 2011 Jun 14;183(9):1014-20
references: 21576295
references: Adv Exp Med Biol. 2011;697:197-220
references: 21120728
references: N Engl J Med. 2008 Apr 10;358(15):1580-9
references: 18403766
references: Acta Otolaryngol. 1966 Mar;61(3):270-8
references: 5960077
references: Hum Vaccin. 2011 Dec;7(12):1389-93
references: 22108037
references: Med J Aust. 2009 Oct 5;191(7):398-401
references: 19807634
references: Epidemiol Infect. 2012 Mar;140(3):439-46
references: 21554780
references: Acta Paediatr Scand. 1983 Jul;72(4):603-9
references: 6624436
references: Am J Hyg. 1959 Mar;69(2):91-111
references: 13626949
references: J Pediatr. 1946 Aug;29:129-42
references: 20994704
references: Pediatrics. 2012 Dec;130(6):e1567-74
references: 23129075
references: MMWR Morb Mortal Wkly Rep. 1982 Nov 26;31(46):617-20, 625
references: 6817072
references: Vaccine. 2009 Oct 19;27(44):6186-95
references: 19815120
references: Acta Otolaryngol. 1957 Nov-Dec;48(5-6):397-403
references: 13508195
references: MMWR Recomm Rep. 1998 May 22;47(RR-8):1-57
references: 9639369